2017
Negative Regulation of Type 2 Immunity
de Kouchkovsky DA, Ghosh S, Rothlin CV. Negative Regulation of Type 2 Immunity. Trends In Immunology 2017, 38: 154-167. PMID: 28082101, PMCID: PMC5510550, DOI: 10.1016/j.it.2016.12.002.BooksConceptsType 2 immunityProtective host responseType 2 responsesAllergic rhinitisAtopic diseasesAtopic dermatitisMillions of individualsHost responseImmune systemImmunityInappropriate activationNegative regulationEnvironmental substancesParasitic helminthsIndustrialized worldHelminthsRhinitisImmunopathologyKey playersAsthmaDermatitisAllergensDiseaseIndividuals
2012
Altered store operated calcium entry increases cyclic 3′,5′‐adenosine monophosphate production and extracellular signal‐regulated kinases 1 and 2 phosphorylation in polycystin‐2‐defective cholangiocytes
Spirli C, Locatelli L, Fiorotto R, Morell CM, Fabris L, Pozzan T, Strazzabosco M. Altered store operated calcium entry increases cyclic 3′,5′‐adenosine monophosphate production and extracellular signal‐regulated kinases 1 and 2 phosphorylation in polycystin‐2‐defective cholangiocytes. Hepatology 2012, 55: 856-868. PMID: 21987453, PMCID: PMC3272110, DOI: 10.1002/hep.24723.Peer-Reviewed Original ResearchMeSH KeywordsAdenylyl CyclasesAnimalsBile DuctsCalciumCalcium ChannelsCalcium SignalingCells, CulturedCyclic AMPCyclic AMP-Dependent Protein KinasesHomeostasisMembrane GlycoproteinsMiceMice, KnockoutMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Models, AnimalPhosphorylationSignal TransductionStromal Interaction Molecule 1TRPP Cation ChannelsVascular Endothelial Growth Factor AConceptsSensor stromal interaction molecule 1Adenylyl cyclase type 6Extracellular signal-regulated kinases 1Signal-regulated kinases 1Overproduction of cAMPStromal interaction molecule 1Orai channelsWild-type miceSOCE activationCAMP productionRapamycin (mTOR) signalingKinase 1ERK pathwayERK1/2 activationHuman diseasesWT cellsMammalian targetDependent activationSTIM-1CAMP/Inappropriate activationCyst growthCystic cholangiocytesPolycystic liver diseaseActivation
2010
Midbrain Activation During Pavlovian Conditioning and Delusional Symptoms in Schizophrenia
Romaniuk L, Honey GD, King JR, Whalley HC, McIntosh AM, Levita L, Hughes M, Johnstone EC, Day M, Lawrie SM, Hall J. Midbrain Activation During Pavlovian Conditioning and Delusional Symptoms in Schizophrenia. JAMA Psychiatry 2010, 67: 1246-1254. PMID: 21135324, DOI: 10.1001/archgenpsychiatry.2010.169.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmygdalaBasal GangliaCase-Control StudiesConditioning, ClassicalCross-Sectional StudiesCuesDelusionsDiagnostic and Statistical Manual of Mental DisordersFemaleHumansMagnetic Resonance ImagingMaleMesencephalonMiddle AgedNeuropsychological TestsPsychotic DisordersSchizophreniaSchizophrenic PsychologySeverity of Illness IndexConceptsHealthy control participantsDelusional symptomsVentral striatumDSM-IV-diagnosed schizophreniaInappropriate activationControl participantsBlood oxygen level-dependent (BOLD) responseAcademic medical centerNegative Syndrome ScaleFunctional magnetic resonance imagingMagnetic resonance imagingRegional brain activationLevel-dependent responsesFunctional magnetic resonanceFunctional neuroimaging studiesPatient groupMedical CenterPavlovian conditioning taskSchizoaffective disorderAbnormal activationSyndrome ScalePatientsResonance imagingMidbrain activationSymptom severityExosome‐release of beta‐catenin: A novel mechanism to antagonize Wnt signaling
Chairoungdua A, Smith D, Pochard P, Hull M, Caplan M. Exosome‐release of beta‐catenin: A novel mechanism to antagonize Wnt signaling. The FASEB Journal 2010, 24: 715.3-715.3. DOI: 10.1096/fasebj.24.1_supplement.715.3.Peer-Reviewed Original ResearchWnt/β-cateninWnt/β-catenin activityDendritic cellsΒ-cateninΒ-catenin activityCD9 expressionE-cadherinTumor metastasisWild-type miceNovel mechanismΒ-catenin protein levelsT cellsΒ-catenin levelsKnockout miceTumor cell metastasisCell metastasisGSK-3βMetastasisCHO cellsLuciferase reporterInappropriate activationCD82 expressionProtein levelsHEK 293T cellsSignificant decrease
2009
Structural basis for EGFR ligand sequestration by Argos
Klein D, Stayrook S, Shi F, Narayan K, Lemmon M. Structural basis for EGFR ligand sequestration by Argos. The FASEB Journal 2009, 23: 883.7-883.7. DOI: 10.1096/fasebj.23.1_supplement.883.7.Peer-Reviewed Original ResearchEpidermal growth factor receptorHuman urokinase-type plasminogen activator receptorDiverse developmental processesClamp-like structureEGF-like domainGrowth factor ligandsArgos functionMammalian counterpartsLigand sequestrationEGF-like modulesUrokinase-type plasminogen activator receptorEGF domainsEGF ligandGrowth factor receptorEssential regulatorStructural basisDevelopmental processesStructural homologuesEGFR ligandsFactor ligandHuman cancersPlasminogen activator receptorFactor receptorErbB/Inappropriate activation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply